Publication Name	World Journal of Gastroenterology
Manuscript ID	2142
Country	Italy

Received	2013-01-31 08:40
Peer-Review Started	2013-01-31 17:06
To Make the First Decision	2013-03-04 11:56
Return for Revision	2013-03-07 16:09
Revised	2013-04-03 00:51
Second Decision	2013-05-09 12:48
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2013-05-10 10:22
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2013-07-16 12:26
Publish the Manuscript Online	2013-07-29 11:18

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Autobiography
Article Title	First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer
Manuscript Source	Invited Manuscript
All Author List	Vanja Vaccaro, Emilio Bria, Isabella Sperduti, Alain Gelibter, Luca Moscetti, Giovanni Mansueto, Enzo Maria Ruggeri, Teresa Gamucci, Francesco Cognetti and Michele Milella
Funding Agency and Grant Number	Funding Agency Grant Number National Ministry of Health and the Italian Association for Cancer Research (AIRC) AIRC fellowship to Vaccaro V
Corresponding Author	Michele Milella, MD, Department of Medical Oncology, Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144 Rome, Italy. michelemilella@hotmail.com
Key Words	Pancreatic cancer; Gemcitabine; Fixed dose-rate; Erlotinib; Prognostic factors; Cutaneous rash; Phase Ⅱ trial
Core Tip	The most important finding reported in this study is the strong predictive value of the appearance of skin rash, related to epidermal growth factor receptor (EGFR)-pathway inhibition. Our data suggest that patients developing any grade of skin rash during the treatment, can achieve disease control and survival comparable to those obtained with more intensive and more toxic chemotherapy. These findings underline the relevance of further investigation of the biological mechanisms related to the occurrence of skin rash upon EGFR blockade in order to identify clinical/molecular biomarkers predicting toxicity and efficacy and to prospectively select a subset of patients who could potentially benefit from Gem/erlotinib.
Publish Date	2013-07-29 11:18
Citation	Vaccaro V, Bria E, Sperduti I, Gelibter A, Moscetti L, Mansueto G, Ruggeri EM, Gamucci T, Cognetti F, Milella M. First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer. World J Gastroenterol 2013; 19(28): 4511-4519
URL	http://www.wjgnet.com/1007-9327/full/v19/i28/4511.htm
DOI	http://dx.doi.org/10.3748/wjg.v19.i28.4511

Full Article (PDF)	WJG-19-4511.pdf
Manuscript File	2142-Review.doc
Answering Reviewers	2142-Answering reviewers.pdf
Copyright License Agreement	2142-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	2142-Language certificate.pdf
Peer-review Report	2142-Peer reviews.pdf
Scientific Editor Work List	2142-Scientific editor work list.doc